Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues
Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported...
Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report
Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176),...
Online Pharmacy Service Drives Jianke.com’s Revenue Growth in H1 2024 Amid Diverse Business Segments
Jianke.com, a China-based smart healthcare service platform, has unveiled its financial report for the first...
Jiangxi Jemincare Secures First Generic Approval for GSK’s Requip in China
Jiangxi Jemincare Group, based in China, has received marketing approval from the National Medical Products...
AstraZeneca to Invest $135 Million in Swedish Biomanufacturing Facility Expansion
AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based biopharmaceutical leader, has announced a plan to...
Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China
Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing...
Sanofi Halts Flu Vaccine Distribution in China Amid Potency Concerns
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of...
Frontier Biotechnologies to Sell 70% of API Unit to Duo Rui Pharma for RMB 10 Million
Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active...
Johnson & Johnson China’s Cardiovascular and Professional Solutions Division Head, Kevin Chen, Resigns for New Opportunities
Johnson & Johnson (J&J, NYSE: JNJ), a leading US multinational conglomerate, has announced the resignation...
Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency
Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952),...
JW Therapeutics’ CAR-T Therapy Carteyva Secures NMPA Approval for Mantle Cell Lymphoma Indication
JW Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
Shanghai-Based ANEXT Commences Clinical Trials for Exosome Product ANEXT FIT CELL in Respiratory Conditions
ANEXT, a Shanghai-based exosome specialist, has launched two clinical studies for their product ANEXT FIT...
Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...
Shanghai BDgene Partners with SPH RD to Develop Hemophilia Treatments Using BDlendi Insulator Technology
Shanghai BDgene Technology Co., Ltd, a leading gene therapy specialist based in China, has entered...
Legend Biotech’s Carvykti Receives NMPA Approval for Relapsed/Refractory Multiple Myeloma After Multi-Center Phase II Study
Legend Biotech Corporation (NASDAQ: LEGN) has secured a significant milestone with the announcement of marketing...
Jiangsu Hengrui’s Vunakizumab Receives NMPA Approval as First Homegrown Autoimmune IL-17A Drug
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...
Luye Pharma’s Subsidiary Boan Bio Reports 2024H1 Revenue Growth and First Full Year of Profitability
Luye Pharma Group, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2186), has announced...
Hinova Pharmaceuticals’ HP515 Receives NMPA Approval for NASH Clinical Study
Hinova Pharmaceuticals Inc., a biotech firm headquartered in Chengdu and listed on the Shanghai Stock...
Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition
Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE:...
Bio-Thera Solutions’ BAT8006 Receives NMPA Approval for Clinical Trial in Recurrent Ovarian Cancer Maintenance Therapy
Bio-Thera Solutions, a biopharmaceutical company based in Guangzhou and listed on the Shanghai Stock Exchange...